Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP10 | P09238 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390084 | 0.83 | CES2 (0.46) | CES2CES1CA1CA2SLC6A3 | |
| SCHEMBL229151 | 0.82 | CES2 (0.42) | CES2CES1CA1CA2DPP4 | |
| SCHEMBL4674968 | 0.82 | DRD2 (0.53) | CES2CES1CA1CA2OPRD1 | |
| SCHEMBL27416408 | 0.81 | CES2 (0.45) | CES2CES1CA1CA2SLC6A3 | |
| SCHEMBL11761384 | 0.81 | OPRM1 (0.48) | CES2CES1SLC6A3 | |
| SCHEMBL227735 | 0.81 | CES2 (0.41) | CES2CES1CA1CA2DPP4 | |
| SCHEMBL373783 | 0.79 | HDAC1 (0.42) | CES2CES1CA1CA2DPP4 | |
| Bromide SCHEMBL10966858 | 0.79 | OPRD1 (0.40) | CES2CES1CA1CA2DPP4 | |
| SCHEMBL3974848 | 0.78 | SLC6A2 (0.40) | CES2CES1CA1CA2OPRD1 | |
| SCHEMBL9866928 | 0.77 | CES2 (0.49) | CES2CES1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101384581-B | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| CN-101384581-A | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-0401707-B1 | Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity | DAIICHI SEIYAKU CO (JP) | 1994-09-21 | — | — | EP | disclosed |
| US-5232924-A | Cardiovascular disorders | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0401707-A1 | Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| US-4366162-A | DEPRESSANT, PSYCHOLOGICAL DISORDERS | AB FERROSAN (SE) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | CES2 877/4885CES1 3357/4885CA1 4738/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | CES2 877/4885CES1 3357/4885CA1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.